Pharmaceutical industry financial support for medical education

Benefit, or undue influence?

Howard Brody

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Presently, the pharmaceutical industry funds about half of the costs of continuing medical education (CME) programs in the U.S. This contributes to the ethical problems that pervade the relationship between medicine and the pharmaceutical industry: trustworthiness and conflicts of interest. The problems are exacerbated by rationalizations prevalent on both sides that deny the ethical concerns. Commercialism and commercial bias are highly visible at large CME gatherings, and available data, while scanty, back up the view that physician attendees' subsequent prescribing practices are influenced by the commercial message. The industry believes that it will recoup $3.56 in increased sales for every dollar that it invests in CME. New guidelines instituted by the Accreditation Council for Continuing Medical Education (ACCME) in 2004 may succeed in reducing excessive commercial influence, especially since the Department of Health and Human Services has also warned the industry of possible anti-kickback violations if firewalls are not erected between CME funding and marketing of drugs. Critics counter that early indicators of improvement are lacking.

Original languageEnglish (US)
Pages (from-to)451-460
Number of pages10
JournalJournal of Law, Medicine and Ethics
Volume37
Issue number3
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Financial Support
Continuing Medical Education
Drug Industry
Medical Education
Industry
United States Dept. of Health and Human Services
Fraud
Conflict of Interest
Accreditation
Financial Management
Marketing
Medicine
Guidelines
Physicians
Costs and Cost Analysis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Health Policy
  • Issues, ethics and legal aspects

Cite this

Pharmaceutical industry financial support for medical education : Benefit, or undue influence? / Brody, Howard.

In: Journal of Law, Medicine and Ethics, Vol. 37, No. 3, 09.2009, p. 451-460.

Research output: Contribution to journalArticle

@article{6f12f8826eb44728a7e9500e3f845f72,
title = "Pharmaceutical industry financial support for medical education: Benefit, or undue influence?",
abstract = "Presently, the pharmaceutical industry funds about half of the costs of continuing medical education (CME) programs in the U.S. This contributes to the ethical problems that pervade the relationship between medicine and the pharmaceutical industry: trustworthiness and conflicts of interest. The problems are exacerbated by rationalizations prevalent on both sides that deny the ethical concerns. Commercialism and commercial bias are highly visible at large CME gatherings, and available data, while scanty, back up the view that physician attendees' subsequent prescribing practices are influenced by the commercial message. The industry believes that it will recoup $3.56 in increased sales for every dollar that it invests in CME. New guidelines instituted by the Accreditation Council for Continuing Medical Education (ACCME) in 2004 may succeed in reducing excessive commercial influence, especially since the Department of Health and Human Services has also warned the industry of possible anti-kickback violations if firewalls are not erected between CME funding and marketing of drugs. Critics counter that early indicators of improvement are lacking.",
author = "Howard Brody",
year = "2009",
month = "9",
doi = "10.1111/j.1748-720X.2009.00406.x",
language = "English (US)",
volume = "37",
pages = "451--460",
journal = "Journal of Law, Medicine and Ethics",
issn = "1073-1105",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Pharmaceutical industry financial support for medical education

T2 - Benefit, or undue influence?

AU - Brody, Howard

PY - 2009/9

Y1 - 2009/9

N2 - Presently, the pharmaceutical industry funds about half of the costs of continuing medical education (CME) programs in the U.S. This contributes to the ethical problems that pervade the relationship between medicine and the pharmaceutical industry: trustworthiness and conflicts of interest. The problems are exacerbated by rationalizations prevalent on both sides that deny the ethical concerns. Commercialism and commercial bias are highly visible at large CME gatherings, and available data, while scanty, back up the view that physician attendees' subsequent prescribing practices are influenced by the commercial message. The industry believes that it will recoup $3.56 in increased sales for every dollar that it invests in CME. New guidelines instituted by the Accreditation Council for Continuing Medical Education (ACCME) in 2004 may succeed in reducing excessive commercial influence, especially since the Department of Health and Human Services has also warned the industry of possible anti-kickback violations if firewalls are not erected between CME funding and marketing of drugs. Critics counter that early indicators of improvement are lacking.

AB - Presently, the pharmaceutical industry funds about half of the costs of continuing medical education (CME) programs in the U.S. This contributes to the ethical problems that pervade the relationship between medicine and the pharmaceutical industry: trustworthiness and conflicts of interest. The problems are exacerbated by rationalizations prevalent on both sides that deny the ethical concerns. Commercialism and commercial bias are highly visible at large CME gatherings, and available data, while scanty, back up the view that physician attendees' subsequent prescribing practices are influenced by the commercial message. The industry believes that it will recoup $3.56 in increased sales for every dollar that it invests in CME. New guidelines instituted by the Accreditation Council for Continuing Medical Education (ACCME) in 2004 may succeed in reducing excessive commercial influence, especially since the Department of Health and Human Services has also warned the industry of possible anti-kickback violations if firewalls are not erected between CME funding and marketing of drugs. Critics counter that early indicators of improvement are lacking.

UR - http://www.scopus.com/inward/record.url?scp=69649103503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69649103503&partnerID=8YFLogxK

U2 - 10.1111/j.1748-720X.2009.00406.x

DO - 10.1111/j.1748-720X.2009.00406.x

M3 - Article

VL - 37

SP - 451

EP - 460

JO - Journal of Law, Medicine and Ethics

JF - Journal of Law, Medicine and Ethics

SN - 1073-1105

IS - 3

ER -